OX390

About Orexo

Orexo is a publicly traded Swedish pharmaceutical company that has evolved from an R&D-focused entity into a commercial organization with a hybrid business model. Its strategic foundation is the proprietary AmorphOX® powder-based drug delivery technology, designed to improve bioavailability and stability for critical medicines. Following the transformative 2025 divestment of its flagship product Zubsolv® in the US, the company is executing a three-pillar growth strategy focused on becoming a global leader in nasal powder delivery, advancing a diversified pipeline to key value inflection points, and establishing technology partnerships.

Therapeutic Areas